ELISAs for complement-dependent cytotoxicity testing
Explore QuidelOrtho ELISAs and high-quality reagents for biological therapeutics research through complement-dependent cytotoxicity testing. Where immune activation meets therapeutic precision.
The complement system is a network of 50+ individual proteins, protein complexes and fragments that drive a host’s innate immune response via three main pathways: alternative, classical and lectin. Complement-dependent cytotoxicity (CDC) is the natural mechanism by which therapeutics, most often humanized antibodies but also other non-antibody proteins and peptides, activate the complement system. This ultimately leads to the formation of the membrane attack complex (MAC), clearance of non-host materials and additional immune system response.
Biological therapeutics can induce CDC. This can be either a negative or positive outcome depending on the desired therapeutic goal:
Negative CDC: Unregulated complement activation contributes to host autoimmune response and downstream adverse effects
Measuring CDC is important for assessing overall biocompatibility, requiring several parameters to accurately evaluate the potential contribution of the complement system.
QuidelOrtho specialty products group (SPG) offers a variety of assays and reagents for CDC assays
CDC assay material
Product description
Catalog #
Complement source and activators
Normal human serum (NHS) ▪ Source of human complement system proteins specially processed for minimal activation
Materials needed for CDC assays that are not provided by QuidelOrtho include:
Biologic therapeutic (antibody/protein/peptide)
Therapeutic target (e.g., target cells)
Assay parameters
The following assay parameters are provided as guidelines only and are not intended to be inclusive of all possible variations of the experiment.
Terms and definitions:
Biologic therapeutic: Therapeutic antibody, peptide or protein
Biologic control: Non-specific and non-therapeutic antibody, peptide or protein
Therapeutic target: Intended target of the biologic therapeutic (e.g., cells)
Control assays
The following reagent and assay suggestions may act as controls for proper materials performance.
Materials
Description
Products needed
Biologic therapeutic + NHS
(–) Control: Evaluate if biologic therapeutic aggregates and activates complement while in soluble form.
NHS: Complement source
CVF: Complement activator
EIA kits: Complement protein detection (see product list section for specific kit recommendations)
Biologic control + NHS
(–) Control: Evaluate if non-therapeutic biological control activates complement.
Therapeutic target + NHS
(–) Control: Evaluate if therapeutic targets activate complement (ex. surface carbohydrate initiates the lectin pathway).
CVF + NHS
(+) Control: Provides data range for comparison if complement is activated in the CDC assay.
CDC assays
The CDC assay combines the biologic therapeutic and its target to evaluate complement activation.
Materials
Description
Products needed
Biologic therapeutic + Therapeutic target + NHS
Evaluate if the combination of the therapeutic biologic and target activates the complement system, leading to CDC. Variations of dilutions, concentrations and incubation times should be considered.
NHS: Complement source
EIA kits: Complement protein detection (see product list section for specific kit recommendations)
QuidelOrtho SPG offers dozens of products for measuring and studying the complement system, including ELISAs, multiplex, antibodies, proteins, serum, depleted sera and reagents.
ELISAs for complement-dependent cytotoxicity testing